Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Context: Observational studies of insulin degludec (degludec) with hypoglycemia events prospectively recorded are lacking. Objective: To evaluate the safety and effectiveness of degludec in patients with type 1 diabetes (T1D) or type 2 diabetes (T2D) switching from other basal insulins in routine care. Design: Results From Real-World Clinical Treatment With Tresiba® was a multinational, multicenter, prospective, observational, single-arm study comprising a 4-week baseline period (preswitch basal insulin) and 12-month follow-up (degludec). Setting: Routine clinical practice. Patients or Other Participants: Insulin-treated patients (≥18 years) with T1D (n = 556) or T2D (n = 611) with treatment plans to initiate degludec. Interventions: Switching to degludec from other basal insulins. Main Outcome Measure: Change from baseline in number of overall hypoglycemic events recorded in patient diaries. Results: In T1D, the 12-month follow-up/baseline rate ratios (95% CI) of overall [0.80 (0.74 to 0.88)], nonsevere [0.83 (0.76 to 0.91)], severe [0.28 (0.14 to 0.56)], and nocturnal [0.61 (0.50 to 0.73)] hypoglycemia suggested significantly lower hypoglycemia rates with degludec (all Ps < 0.001). At 12 months, HbA1c, fasting plasma glucose (FPG), and basal insulin dosage decreased significantly. Body weight increased, and treatment satisfaction improved significantly. In T2D, the hypoglycemia rate ratios were overall [0.46 (0.38 to 0.56)], nonsevere [0.53 (0.44 to 0.64)], and nocturnal [0.35 (0.20 to 0.62)] (all Ps < 0.001; too few events for analysis of severe hypoglycemia). At 12 months, HbA1c and FPG decreased significantly. Body weight and insulin dosages remained unchanged, and treatment satisfaction was significantly improved. Conclusions: In a routine clinical care setting, switching to degludec from other basal insulins was associated with significantly lower rates of hypoglycemia, improved glycemic control, and treatment satisfaction in patients with T1D or T2D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several trials have demonstrated that physiologic regimens using basal insulin analogs may reduce hypoglycemia, and bolus insulin analogs may result in better control of PPG excursions for most persons with T1D.1132–1137”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1136]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cook, R. J., Dickens, B. M., & Fathalla, M. F. (2003) · Reproductive Health and Human Rights · doi:10.1093/acprof:oso/9780199241323.003.0025 · Cited by 10,769
Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003) · Medical Care · doi:10.1097/01.mlr.0000062554.74615.4c · Cited by 4,700 · cited 1×
“For DTSQ-s, a difference of more than half a standard deviation of the baseline score is considered a meaningful change (34).”
BackgroundSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825 · cited 1×
“barrier to obtaining good glycemic control (1, 2).”
BackgroundGarrison, L. P., Neumann, P. J., Erickson, P., Marshall, D., & Mullins, C. D. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00186.x · Cited by 700 · cited 1×
“trial conditions in a specific patient population (16, 17).”
BackgroundPeyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574
Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications
Frier, B. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.170 · Cited by 481 · cited 1×
“Regardless of severity, hypoglycemic events can disrupt patients’ daily functioning and quality of life (35, 36), along with an added cost burden (37).”
BackgroundHypoglycemia, Diabetes, and Cardiovascular Events
Desouza, C. V., Bolli, G. B., & Fonseca, V. (2010) · Diabetes Care · doi:10.2337/dc09-2082 · Cited by 443 · cited 1×
“Regardless of severity, hypoglycemic events can disrupt patients’ daily functioning and quality of life (35, 36), along with an added cost burden (37).”
BackgroundHeise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397 · cited 7×
“The majority of patients switched from glargine (U100 or U300) to degludec in both the T1D group (63.8”
InfluentialRatner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346 · cited 1×
“cemic levels, as well as other real-world studies (11, 13, 14, 19, 23).”
BackgroundAssessment of the Impact of Fear of Hypoglycemic Episodes on Glycemic and Hypoglycemia Management
Leiter, L. A., Yale, J., Chiasson, J., Harris, S. B., & Kleinstiver, P. W. (2005) · Cited by 250
Hypoglycemia: An overview of fear of hypoglycemia, quality-of-life, and impact on costs
Fidler, C., Elmelund Christensen, T., & Gillard, S. (2011) · Journal of Medical Economics · doi:10.3111/13696998.2011.610852 · Cited by 244
Wysham, C., Bhargava, A., Chaykin, L., de la Rosa, R., Handelsman, Y., Troelsen, L. N., Kvist, K., & Norwood, P. (2017) · JAMA · doi:10.1001/jama.2017.7117 · Cited by 221 · cited 1×
“cemic levels, as well as other real-world studies (11, 13, 14, 19, 23).”
BackgroundLane, W., Bailey, T. S., Gerety, G., Gumprecht, J., Philis-Tsimikas, A., Hansen, C. T., Nielsen, T. S. S., Warren, M., Group Information, & 1, T. S. (2017) · JAMA · doi:10.1001/jama.2017.7115 · Cited by 206
Observational studies: going beyond the boundaries of randomized controlled trials
Yang, W., Zilov, A. V., Soewondo, P., Bech, O. M., Sekkal, F., & Home, P. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(10)70002-4 · Cited by 180 · cited 1×
“trial conditions in a specific patient population (16, 17).”
BackgroundHeise, T., Nørskov, M., Nosek, L., Kaplan, K., Famulla, S., & Haahr, H. L. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12938 · Cited by 118
Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters-Weijnen, C., Forsén, T., Galstyan, G., Geelhoed-Duijvestijn, P., Goldfracht, M., Gydesen, H., et al. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.05.004 · Cited by 71
Brod, M., Rana, A., & Barnett, A. H. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.743457 · Cited by 60
Tibaldi, J., Hadley‐Brown, M., Liebl, A., Haldrup, S., Sandberg, V., Wolden, M. L., & Rodbard, H. W. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13616 · Cited by 46 · cited 2×
“As expected, higher rates of hypoglycemia were observed in ReFLeCT compared with observational chart review or registry studies (22, 29).”
MethodResultSelf-citationSiegmund, T., Tentolouris, N., Knudsen, S. T., Lapolla, A., Prager, R., Phan, T., Wolden, M. L., Schultes, B., & for the EU‐TREAT study group (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13149 · Cited by 44
Self-citationDavies, M., Sasaki, T., Gross, J. L., Bantwal, G., Ono, Y., Nishida, T., Tojjar, D., & Seino, H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12573 · Cited by 33
Landstedt‐Hallin, L. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1058252 · Cited by 31
Galasso, S., Facchinetti, A., Bonora, B. M., Mariano, V., Boscari, F., Cipponeri, E., Maran, A., Avogaro, A., Fadini, G. P., & Bruttomesso, D. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.08.002 · Cited by 31
Self-citationEvans, M., McEwan, P. C., & FOOS, V. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.975234 · Cited by 30
Harris, S. B., Leiter, L. A., Yale, J., Chiasson, J., Kleinstiver, P. W., & Sauriol, L. (2007) · Canadian Journal of Diabetes · doi:10.1016/s1499-2671(07)11008-x · Cited by 29 · cited 1×
“Regardless of severity, hypoglycemic events can disrupt patients’ daily functioning and quality of life (35, 36), along with an added cost burden (37).”
BackgroundShimoda, S., Sato, M., Sekigami, T., Motoshima, H., Yoshimura, R., Fukuda, K., Matsuo, Y., Noda, H., Okubo, M., Ichimori, S., et al. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12496 · Cited by 19
Kobuke, K., Yoneda, M., Nakanishi, S., Ohno, H., Maeda, S., & Egusa, G. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12373 · Cited by 16
Bohn, B., Zimmermann, A., Wagner, C., Merger, S. R., Dunstheimer, D., Kopp, F., Gollisch, K. S. C., Zindel, V., & Holl, R. W. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.031 · Cited by 15
Urakami, T., Kuwabara, R., Aoki, M., Okuno, M., & Suzuki, J. (2015) · Endocrine Journal · doi:10.1507/endocrj.ej15-0245 · Cited by 14
Ghosal, S., Sinha, B., & Gangopadhyay, K. K. (2016) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2016.01.013 · Cited by 9
Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data
Kaku, K., Wolden, M. L., Hyllested-Winge, J. L., & Nørtoft, E. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0225-z · Cited by 6 · cited 1×
“cemic levels, as well as other real-world studies (11, 13, 14, 19, 23).”
BackgroundSelf-citationSuzuki, J., Yamakawa, T., Nagakura, J., Shigematsu, E., Kadonosono, K., & Terauchi, Y. (2016) · Diabetology International · doi:10.1007/s13340-016-0275-x · Cited by 4
Research works printed but not linked: 1
- Bradley C The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In: Bradley C, ed. Handbook of Psychology and Diabetes: A Guide to Psychological Measurement in Diabetes Research and Practice. Chur, Switzerland: Harwood Academic Publishers; 1994:111–132.
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Valentine, W. J., Hoog, M., Mody, R., Belger, M., & Pollock, R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14979 · Cited by 28
“For basal insulin therapy, hypoglycaemia event rates were taken from the baseline period of the REFLECT real-world study.(20)”
MethodConget, I., Mangas, M. Á., Morales, C., Caro, J., Giménez, M., Borrell, M., & Delgado, E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01153-4 · Cited by 20
“, in which the switch to degludec from another BI was associated with significantly lower rates of hypoglycemia and improved glycemic control [41].”
BackgroundJENDLE, J. H., Ericsson, Å., Ekman, B., Sjöberg, S., Gundgaard, J., Fernandes, J. D. R., MÅRDBY, A.-C. M., Hunt, B., Malkin, S. J. P., & Thunander, M. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2020.1805454 · Cited by 15
Self-citationMody, R., Valentine, W. J., Hoog, M. M., Sharland, H., & Belger, M. A. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.30.2.153 · Cited by 13
Metadata
- Authors
- Fadini, G. P., Feher, M., Hansen, T. K., de Valk, H. W., Koefoed, M. M., Wolden, M., Zimmermann, E., & Jendle, J.
- Affiliations
- University of Padua (IT)
- University of Surrey (GB)
- Aarhus University Hospital (DK)
- Department of Internal Medicine, University Medical Center Utrecht, CX Utrecht, Netherlands
- Novo Nordisk (Denmark) (DK)
- Örebro University (SE)
- Corresponding author
- Fadini, Gian Paolo
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2019-08-09
- Volume
- 104
- Issue
- 12
- Pages
- 5977-5990
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC6812737
- OpenAlex
- W2968305708
- Cited by
- 27
- References
- 34
- Citations by year
- 2025: 3 · 2024: 7 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 6
- FWCI
- 3.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- insulin degludec, basal insulin switching, hypoglycemia, type 1 diabetes, type 2 diabetes, nocturnal hypoglycemia, HbA1c, fasting blood glucose, treatment satisfaction, body weight, insulin dose, real-world clinical practice, patient diary, insulin analogues, glycemic control, safety and effectiveness
- MeSH terms
- Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Europe, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemia, Male, Middle Aged, Insulin, Long-Acting, Drug Substitution, Insulins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.